Muneer H. Abidi

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 868 citations · Full text

Hematological Malignancy, Dexamethasone Versus Lenalidomide, Oncology +9

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 726 citations · Full text

Lymphoid Neoplasia, Cell Therapy, Transplantation +10

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study

Richard A. Nash, Peter A. McSweeney, Leslie J. Crofford et al. · Blood · 2007 · 257 citations · Full text

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Brian G.M. Durie, Antje Hoering, Rachael Sexton et al. · Blood Cancer Journal · 2020 · 246 citations · Full text

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee et al. · Blood · 2018 · 237 citations · Full text